Medicare Enrolled
Dr. Dennis Novak, MD
Pulmonary Disease · Newport Beach, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Novak from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Novak?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Novak
Dr. Dennis Novak is a pulmonary disease specialist in Newport Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Novak performed 3,437 Medicare services across 1,955 unique beneficiaries.
Between the years covered by Open Payments, Dr. Novak received a total of $10,030 from 38 pharmaceutical and/or device companies across 427 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Novak is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 9% volume in CA
$10,030 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,437
Medicare services
Top 9% in CA for pulmonary disease
1,955
Unique beneficiaries
$48
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~181 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Airflow rate measurement test A test that measures the rate of airflow. This procedure assesses how quickly air moves. |
723 | $33 | $95 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
565 | $102 | $170 |
| Betamethasone steroid injection An injection containing a combination of betamethasone acetate and betamethasone sodium phosphate. |
528 | $5 | $8 |
| Nitric oxide gas level test A test that measures the level of nitric oxide gas in the body. |
232 | $17 | $40 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
175 | $51 | $98 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
168 | $71 | $120 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
140 | $49 | $97 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
139 | $8 | $60 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
136 | $12 | $32 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
135 | $35 | $126 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
91 | $146 | $235 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
80 | $33 | $40 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
79 | $72 | $79 |
| New patient office visit, complex (60-74 min) | 49 | $175 | $399 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
43 | $23 | $95 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
37 | $15 | $24 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
35 | $74 | $126 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
30 | $29 | $77 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
15 | $33 | $40 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
13 | $282 | $300 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
13 | $43 | $77 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $134 | $315 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2023 ↗$10,030
Total received (2018-2023)
Avg $1,672/year across 6 years
Top 16% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
427
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,930 (99.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$1,667
2022
$1,914
2021
$1,665
2020
$1,095
2019
$1,949
2018
$1,742
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Mylan Specialty L.P.
$251
AstraZeneca Pharmaceuticals LP
$238
GlaxoSmithKline, LLC.
$193
Regeneron Healthcare Solutions, Inc.
$163
Takeda Pharmaceuticals U.S.A., Inc.
$161
Boehringer Ingelheim Pharmaceuticals, Inc.
$143
Grifols USA, LLC
$130
Amgen Inc.
$83
Electromed, Inc.
$67
Philips Electronics North America Corporation
$52
Insmed, Inc.
$46
Baxter Healthcare
$31
Genentech USA, Inc.
$25
Paratek Pharmaceuticals, Inc.
$24
SANOFI PASTEUR INC.
$22
United Therapeutics Corporation
$22
Merck Sharp & Dohme LLC
$16
Top 3 companies account for 40.9% of 2023 payments
All-time payments by company (2018-2023) ›
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,095
AstraZeneca Pharmaceuticals LP
$1,591
GlaxoSmithKline, LLC.
$1,186
Mylan Specialty L.P.
$781
Grifols USA, LLC
$694
Takeda Pharmaceuticals U.S.A., Inc.
$517
Regeneron Healthcare Solutions, Inc.
$414
Philips Electronics North America Corporation
$329
Genentech USA, Inc.
$298
Sunovion Pharmaceuticals Inc.
$292
Insmed, Inc.
$208
Amgen Inc.
$181
Advanced Respiratory, Inc
$124
Janssen Pharmaceuticals, Inc
$115
PFIZER INC.
$112
Electromed, Inc.
$99
Paratek Pharmaceuticals, Inc.
$93
Baxter Healthcare
$89
Teva Pharmaceuticals USA, Inc.
$66
GENZYME CORPORATION
$66
Covis Pharma GmBH
$66
United Therapeutics Corporation
$64
Merck Sharp & Dohme Corporation
$56
Actelion Pharmaceuticals US, Inc.
$54
Octapharma USA, Inc.
$49
Allergan Inc.
$47
Circassia Pharmaceuticals Inc
$42
Shire North American Group Inc
$41
SANOFI PASTEUR INC.
$39
E.R. Squibb & Sons, L.L.C.
$37
CSL Behring
$35
Pulmonx Corporation
$29
Harmony Biosciences LLC
$29
Shionogi Inc
$24
Endogastric Solutions, Inc
$20
ADVANCED RESPIRATORY, INC
$17
Merck Sharp & Dohme LLC
$16
Sanofi Pasteur Inc.
$14
Top 3 companies account for 48.6% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · AIRSUPRA · ALVESCO · ASMANEX · AVYCAZ · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CUTAQUIG · CUVITRU · DUPIXENT · Dymista · ELIQUIS · ESOPHYX · Esbriet · FARXIGA · FASENRA · FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE · FLUZONE HIGH-DOSE · Fetroja · GLASSIA · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hizentra · LONHALA MAGNAIR · Life 2000 Ventilation System · NUCALA · NUZYRA · OFEV · OPSUMIT MACITENTAN · PREVNAR 13 · PREVNAR 20 · PROAIR · ProAir Digihaler · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · QVAR · Respiratoriy Care Undiv · S&RC Und · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SYMBICORT · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · The VitalCough System · Trilogy 100 · UPTRAVI · Utibron · Wakix · XARELTO · Xembify · Xolair · YUPELRI · Yupelri · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
116
Per 100K population
3.7
County median income
$113,702
Nearest hospital
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Novak is a clinical cardiology specialist, with above-average Medicare volume (top 9% in CA), with low-engagement industry engagement in the top 16% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Novak experienced with airflow rate measurement test?
Based on Medicare claims data, Dr. Novak performed 723 airflow rate measurement test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Novak receive payments from pharmaceutical companies?
Yes. Dr. Novak received a total of $10,030 from 38 companies across 427 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Novak's costs compare to other pulmonary diseases in Newport Beach?
Dr. Novak's average Medicare payment per service is $48. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Novak) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Newport Beach
Browse pulmonary diseases in Newport Beach ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology